Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections

D. L. Hemsell, G. D. Wendel, S. A. Gall, E. R. Newton, R. S. Gibbs, R. A. Knuppel, T. W. Lane, R. L. Sweet

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5%, and 12.2% for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.

Original languageEnglish (US)
Pages (from-to)722-727
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume158
Issue number3 II SUPPL.
StatePublished - 1988

Fingerprint

Cefotetan
Cefoxitin
Obstetrics
Pelvic Infection
Infection
Endometritis
Pelvic Inflammatory Disease
Therapeutics
Safety

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Hemsell, D. L., Wendel, G. D., Gall, S. A., Newton, E. R., Gibbs, R. S., Knuppel, R. A., ... Sweet, R. L. (1988). Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. American Journal of Obstetrics and Gynecology, 158(3 II SUPPL.), 722-727.

Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. / Hemsell, D. L.; Wendel, G. D.; Gall, S. A.; Newton, E. R.; Gibbs, R. S.; Knuppel, R. A.; Lane, T. W.; Sweet, R. L.

In: American Journal of Obstetrics and Gynecology, Vol. 158, No. 3 II SUPPL., 1988, p. 722-727.

Research output: Contribution to journalArticle

Hemsell, DL, Wendel, GD, Gall, SA, Newton, ER, Gibbs, RS, Knuppel, RA, Lane, TW & Sweet, RL 1988, 'Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections', American Journal of Obstetrics and Gynecology, vol. 158, no. 3 II SUPPL., pp. 722-727.
Hemsell, D. L. ; Wendel, G. D. ; Gall, S. A. ; Newton, E. R. ; Gibbs, R. S. ; Knuppel, R. A. ; Lane, T. W. ; Sweet, R. L. / Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. In: American Journal of Obstetrics and Gynecology. 1988 ; Vol. 158, No. 3 II SUPPL. pp. 722-727.
@article{84a8330c56584834bb9264b747e1c4f5,
title = "Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections",
abstract = "Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5{\%}, and 12.2{\%} for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.",
author = "Hemsell, {D. L.} and Wendel, {G. D.} and Gall, {S. A.} and Newton, {E. R.} and Gibbs, {R. S.} and Knuppel, {R. A.} and Lane, {T. W.} and Sweet, {R. L.}",
year = "1988",
language = "English (US)",
volume = "158",
pages = "722--727",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3 II SUPPL.",

}

TY - JOUR

T1 - Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections

AU - Hemsell, D. L.

AU - Wendel, G. D.

AU - Gall, S. A.

AU - Newton, E. R.

AU - Gibbs, R. S.

AU - Knuppel, R. A.

AU - Lane, T. W.

AU - Sweet, R. L.

PY - 1988

Y1 - 1988

N2 - Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5%, and 12.2% for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.

AB - Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5%, and 12.2% for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.

UR - http://www.scopus.com/inward/record.url?scp=0023852284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023852284&partnerID=8YFLogxK

M3 - Article

C2 - 3281462

AN - SCOPUS:0023852284

VL - 158

SP - 722

EP - 727

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3 II SUPPL.

ER -